Evidence map›Paper›PMID 41790140›Full record

ArticleDermatologie (Heidelberg, Germany)2026

[Postthrombotic syndrome: an update].

Stefanie Reich-Schupke

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Stefanie Reich-SchupkePrivatpraxis für Haut- und Gefäßmedizin, Hertener Str. 27, 45657, Recklinghausen, Deutschland. info@haut.nrw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postthrombotic syndrome (PTS) is the most common chronic late complication after deep vein thrombosis (DVT): approximately 20-50% develop symptoms and a severe disease course with venous ulceration occurs in roughly 5-10%. The trigger is persistent venous hypertension caused by residual obstruction from incomplete recanalization and/or valve destruction leading to reflux; inflammatory processes further damage the vein wall and valves. Clinically, patients report heaviness, pain, tightness, edema, cramps and skin changes (hyperpigmentation, eczema, lipodermatosclerosis), potentially progressing to venous ulcers. The diagnosis is primarily clinical (typically within 18-24 months after DVT) and should be assessed with the Villalta score; duplex ultrasound is the standard imaging method to evaluate obstruction and reflux, although ultrasound findings do not always correlate with symptom severity. Major risk factors include proximal/iliofemoral DVT, recurrent thrombosis, obesity and delayed or inadequate initial treatment. Prevention and first-line management focus on early and adequate anticoagulation, mobilization and consistent compression therapy (often compression classes II-III) combined with regular exercise or training; for persistent edema, adjustable compression devices or intermittent pneumatic compression can be used. In severe, refractory PTS with pelvic vein obstruction, recanalization and stenting can be considered; venous ulcers require structured wound treatment.

Indexed as

Postthrombotic SyndromeVenous ThrombosisAnticoagulantsHumansRisk FactorsVaricose UlcerAnticoagulantsCompression therapyObstructionRefluxVenous hypertensionVillalta score

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.